EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects

Meng-Jie Zhang, Yirong Chen, Caixia Zhang, Xiaofeng Bian, Xiangyang Zhang, Shijia Huang, Bowen Yang, Siyan Lu, Xueting Fu, Wei Zhao, Xu-Dong Kong, Shuli Zhao

Cellular Oncology · 2025

DOI: 10.1007/s13402-025-01105-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Meng-Jie Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. Hauptthemen laut MEDLINE: Peptides, Cyclic, Receptor, EphA2, Lutetium, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peptides, CyclicReceptor, EphA2LutetiumRadioisotopesProtein Kinase InhibitorsAnimalsHumansCell Line, TumorMice, Inbred C57BLTissue DistributionMiceFemaleDrug SynergismPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

Cancer immunotherapyCyclic peptideEphA2PET/CT imagingPhage selectionTheranostics

Substanzen

Peptides, CyclicReceptor, EphA2LutetiumLutetium-177RadioisotopesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
  • State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 429 Zhangheng Road, Shanghai, 201203, China.
  • General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
  • College of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Department of Pathology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. zhaowei_njmu@163.com.
  • State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 429 Zhangheng Road, Shanghai, 201203, China. xudong.kong…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, M. J., Chen, Y., Zhang, C., Bian, X., Zhang, X., Huang, S., Yang, B., Lu, S., Fu, X., Zhao, W., Kong, X. D., & Zhao, S. (2025). Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects. Cellular Oncology. https://doi.org/10.1007/s13402-025-01105-1

Vancouver

Zhang MJ, Chen Y, Zhang C, Bian X, Zhang X, Huang S, et al. Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects. Cellular Oncology. 2025. doi:10.1007/s13402-025-01105-1

BibTeX
@article{Zhang2025,
  author = {Zhang, Meng-Jie and Chen, Yirong and Zhang, Caixia and Bian, Xiaofeng and Zhang, Xiangyang and Huang, Shijia and Yang, Bowen and Lu, Siyan and Fu, Xueting and Zhao, Wei and Kong, Xu-Dong and Zhao, Shuli},
  title = {Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-025-01105-1}
}
Kostenlos starten →